The FDA has issued a complete response letter to Lundbeck and Otsuka, scuppering their ambition to launch the atypical antipsychotic Rexulti—in combination with Viatris’ Zoloft—as a novel treatment for post-traumatic stress disorder. More: FDA turns down Lundbeck, Otsuka's Rexulti in
read more
EMA opinion supports expanded use of TREMFYA in phase 3 UC treatment More: Guselkumab receives CHMP backing for subcutaneous induction in ulcerative colitis Source: News
read more
BlueRock begins phase 3 study of bemdaneprocel in Parkinson’s disease More: First patient treated in pivotal trial of Parkinson’s cell therapy Source: News
read moreHealth officials are expected to link Tylenol use during early pregnancy to autism and propose a potential treatment in leucovorin, a med used to counter the toxicity of certain chemotherapies, according to the newspaper. More: In Trump's 'answer' to autism,
read moreWith a Sept. 29 deadline looming for pharmaceutical companies to adhere to President Donald Trump’s most favored nation drug pricing system in the U.S., Bristol Myers Squibb has revealed that it will offer schizophrenia drug Cobenfy in the U.K. for
read moreAs Halloween approaches, Exact Sciences is warding off a particularly terrifying occurrence: skipping colorectal cancer screening. More: Exact Sciences scares up spooky season Cologuard campaign starring Matthew Lillard Source: fierce
read more© 1994 - 2025 B.M. Pharmaceuticals